Skip to main content

Table 2 Toxicity

From: Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

Toxicity All DL n (%) DL1 (n) DL2 (n) DL3 (n)
  n = 20 n = 7 n = 7 n = 6
Grade All Gr. 3 Gr. 4 All Gr. 3/4 All Gr. 3/4 All Gr. 3/4
Hematologic       
Neutropenia 14 (70) 3 (15) 5 (25) 5 2 3 2 6 4
Thrombopenia 11 (55) 1 ( 5) 0 (0) 4 1 4 0 3 0
Anaemia 10 (50) 0 (0) 0 (0) 3 0 4 0 3 0
Gastrointestinal       
Diarrhoea 15 (75) 5 (25) 0 (0) 6 1 4 2* 5 2*
Nausea 13 (65) 0 (0) 0 (0) 7 0 4 0 2 0
Vomiting 6 (30) 1 (5) 0 (0) 5 1 1 0 0 0
Stomatitis 14 (70) 0 (0) 0/ 0 6 0 3 0 5 0
Other Mucositis 5 (25) 0 (0) 0 (0) 1 0 1 0 3 0
Bowel Obstruction 1 (5) 0 (0) 1 (5) 0 0 0 1 0 0
General disorders       
Fatigue 16 (80) 0 (0) 0 (0) 5 0 5 0 6 0
Skin toxicity 18 (90) 3 (15) 0 (0) 6 1 6 2 6 0
Paronychia 6 (30) 1 (5) 0 (0) 0 0 2 0 4 1
  1. *One patient fulfilling DLT criteria.